Nestle Maggi Controversy: SC revives Rs 640 crore class action suit

Published On 2019-01-04 08:00 GMT   |   Update On 2021-08-16 12:14 GMT

The Consumer Affairs Ministry had in 2015 filed a complaint against Nestle India before the NCDRC using a provision for the first time in the nearly three-decade-old Consumer Protection Act.


NEW DELHI: The Supreme Court Thursday revived the government case in National Consumer Disputes Redressal Commission (NCDRC) against Nestle India seeking damages of Rs. 640 crore alleging unfair trade practices, false labelling and misleading advertisements.


The top court had on December 16, 2015, stayed the proceedings before the NCDRC and directed the CFTRI (Central Food Technological Research Institute, Mysuru) to place its test report before it.


A bench of Justices D Y Chandrachud and Hemant Gupta was told by senior advocate Abhishek Manu Singhvi, appearing for Nestle India, that tests reports of the Mysuru lab had been submitted and it found that lead content in Maggi noodles was well within the limit.


"Why should we be eating Maggi with lead in it?", Justice Chandrachud asked Mr Singhvi, who replied that there was some amount of lead in various other products.


The bench said the report of CFTRI, where the samples of Maggi noodles were tested following earlier orders of the court, will form the basis for the proceedings before the NCDRC.


"We are of the view that CFTRI report is evaluated by the NCDRC in the complaint before it. It will not be appropriate for this court to pre-empt the jurisdiction of NCDRC... All the rights and contentions of the parties will remain open," the bench said.


During the hearing, Additional Solicitor General Vikramjit Banerjee, appearing for Centre said that in the wake of the Mysuru lab report the matter should go back to NCDRC and stay on the proceedings should be vacated.


Mr Singhvi said the matter has now become infructuous as the report is in my favour and presence of MSG (monosodium glutamate) was not found.


He along with senior advocate Arvind Dattar opposed sending the matter back to NCDRC saying nothing remains to be decided after the lab report.




"Why should we usurp the power of NCDRC. We will send the lab reports to the commission and them ask to dispose of the complaint filed before it," the bench said adding that the appeal against the Bombay High Court order which had in 2015 quashed the Food Safety Standards Authority of India (FSSAI) ban order against Nestle's Maggi noodle will be heard at a later stage.


The Consumer Affairs Ministry had in 2015 filed a complaint against Nestle India before the NCDRC using a provision for the first time in the nearly three-decade-old Consumer Protection Act.


It had filed a complaint against Nestle for causing harm to Indian consumers by allegedly indulging in unfair trade practices and false labelling related to the Maggi noodles product.


It was for the first time that the government had taken action under Section 12-1-D of the Consumer Protection Act, under which both the Centre and states have powers to file complaints.


In the petition filed before the NCDRC, the ministry had charged that Nestle India has misled consumers claiming that its Maggi noodle was healthy -- "Taste bhi healthy bhi".


Nestle had to withdraw its instant noodles brand Maggi from the market over allegations of high lead content and presence of MSG.


The food safety regulator FSSAI had banned Maggi noodles after it found the excess level of lead in samples, terming it as "unsafe and hazardous" for human consumption.


Also Read: Nestle raises stake in food allergy drug developer Aimmune
Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News